Skip to main content

Is Zepbound Covered by Insurance? A Payer-by-Payer Guide

By Last updated:

Whether Zepbound is covered by insurance depends less on which insurance card you carry than on whether your plan sponsor — usually your employer — chose to buy weight-loss drug coverage at all. That’s the structure hiding under every confusing answer in this space: the same insurer covers Zepbound generously for one company’s employees and not at all for another’s. This guide walks the landscape payer by payer, then the prior-authorization criteria, then the appeal playbook that moves people from “denied” to “covered.”

The three-layer answer

  1. Does your plan cover weight-loss medications as a category? Employers opt in or out. If the category is excluded, no formulary news helps — your paths are the appeal-via-other-indication route (sleep apnea, below) or self-pay.
  2. Is Zepbound on the formulary, and at what tier? This is where the PBM (Caremark, Express Scripts, Optum) news matters.
  3. Can you clear the prior authorization? Almost everyone faces one; the criteria are predictable and beatable with documentation.

Payer by payer: the 2026 landscape

CVS Caremark (the PBM behind many Aetna and employer plans): the year’s biggest story. Caremark dropped Zepbound from standard commercial formularies in mid-2025 in favor of Wegovy — forcing switches for millions — then reversed: effective October 1, 2026, Zepbound returns as a preferred option, co-tiered with Wegovy. [2] No tier penalty for choosing either. Two caveats: the standard template covers roughly 25–30 million members, but sponsor opt-outs still override it, and ~94% of Caremark plans keep prior authorization, with roughly 40% requiring a documented trial of another weight intervention first. If you were forced onto Wegovy in 2025 and want back, October 1 is your date — ask your prescriber to queue the PA.

So, does Aetna cover Zepbound? Aetna commercial plans largely follow Caremark’s formulary — meaning the October reversal applies where the sponsor hasn’t excluded the category — with the usual PA. Aetna’s Medicare plans follow the Medicare rules below instead.

Express Scripts / Cigna and Optum / UnitedHealthcare: both generally include Zepbound and Wegovy on standard commercial formularies with PA, again subject to sponsor opt-outs — exact tiering shifts with each plan year, which is why the three-question phone call below beats any published grid. The operational advice is identical everywhere: call the number on your card and ask three questions — is Zepbound on my formulary, what tier, and what does the PA require?

Medicare: Part D still can’t cover drugs for weight loss alone — but two real doors exist. First, Zepbound’s obstructive sleep apnea indication: Part D plans may cover it as an OSA treatment, anchored on a sleep-study diagnosis of moderate-to-severe OSA. Second, the Medicare GLP-1 Bridge — a Medicare program running July 1, 2026 through December 31, 2027 — covers GLP-1s at $50/month for anyone with Part D coverage, whatever plan they’re in. For Zepbound it covers only the KwikPen (not single-dose pens or vials); Wegovy pen and pill are covered too. You need prior approval and a qualifying BMI, and your prescriber certifies you’re in a diet-and-exercise program. [3] The catch for this page’s readers: people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease aren’t eligible for the Bridge — they go through their own Part D plan instead. So if you’re on Medicare with diagnosed OSA, ask your plan specifically about coverage under that indication — it’s the strongest single lever in the Medicare conversation.

Medicaid: varies by state — a minority of states cover GLP-1s for obesity, more cover the OSA/diabetes indications. Your state’s preferred drug list is the authority.

What Zepbound prior authorization actually requires

The criteria repeat across payers with local variations:

  • BMI thresholds: ≥30, or ≥27 with at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes, OSA). Recent chart-documented values — not self-report.
  • Lifestyle-program participation: documented diet/exercise efforts, sometimes a formal program for 3–6 months. A prescriber note describing your regimen usually satisfies it; silence in the chart doesn’t.
  • Step therapy (the ~40% of plans): trial of another intervention — often an older weight-loss medication or Wegovy — with outcome documented.
  • For the OSA route: the sleep study is the document. Moderate-to-severe diagnosis (AHI ≥15) plus, on some plans, intolerance or inadequate response to CPAP documented.
  • Renewals typically require demonstrated response — commonly ≥5% weight loss — so keep weigh-ins in the chart after approval, not just before.

The appeal playbook

GLP-1 denials get overturned often enough that one real appeal cycle is always worth it:

  1. Read the denial letter for the stated reason — appeals that answer the actual criterion win; generic ones don’t.
  2. Match documents to the reason: BMI history and comorbidity list; the sleep study for OSA; program-participation notes; prior-medication outcomes for step therapy.
  3. Letter of medical necessity from your prescriber naming the criterion and the evidence — one page, specific.
  4. Escalate: internal appeal → second-level → external review (independent, state-mandated, and where a surprising share of these are won). Deadlines are on the letter; don’t sit on them.
  5. Reframe if the category is excluded: a weight-loss exclusion doesn’t automatically exclude the OSA indication — coverage under a different diagnosis is a different request, not a re-ask.

If every layer fails, the fallback stack is the Zepbound savings guide: the $25 card where coverage exists, the discounted self-pay tracks, and LillyDirect KwikPen or vials from $299/month. And if the coverage politics push you toward tirzepatide’s other brand instead, Mounjaro vs Zepbound explains how the same molecule wears two insurance costumes.

Frequently Asked Questions

Is Zepbound covered by insurance?

It depends on your plan sponsor, not just your insurer. Many commercial plans cover Zepbound with prior authorization, but employers can opt out of weight-loss drug coverage entirely. The big 2026 shift: CVS Caremark returns Zepbound to its standard formularies October 1 as a preferred option alongside Wegovy.

Does Medicare cover Zepbound?

Not through Part D for weight loss alone — but Part D plans may cover it for the obstructive sleep apnea indication. Separately, the Medicare GLP-1 Bridge (July 2026 through December 2027) covers the Zepbound KwikPen at $50/month for anyone with Part D who gets prior approval and meets the BMI criteria; people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease aren’t eligible and go through their Part D plan instead. If you have OSA, ask your plan specifically about the OSA indication.

What does Zepbound prior authorization require?

Typically: BMI ≥30 (or ≥27 with a weight-related condition), documented participation in diet/exercise efforts, and sometimes trial of another weight intervention first. For sleep apnea coverage, a sleep-study diagnosis of moderate-to-severe OSA is the anchor document.

What if my insurance denies Zepbound?

Appeal — GLP-1 denials get overturned regularly. Match the denial reason with documentation (BMI history, comorbidities, sleep study, prior program participation), have your prescriber file a letter of medical necessity, and escalate to external review if needed. If the exclusion holds, LillyDirect self-pay (KwikPen or vials) starts at $299/month at 2.5 mg and $399 at 5 mg; higher doses are $449 if you refill within 45 days, otherwise $499–$699.

Which insurance covers Wegovy vs Zepbound for weight loss?

Through September 2026, CVS Caremark’s standard formularies prefer Wegovy; from October 1 both sit co-preferred. Express Scripts and Optum generally include both with PA. The deciding layer is always whether your employer bought weight-loss coverage at all.

Sources

  1. Zepbound coverage & savings — official (Lilly)
  2. Managed Healthcare Executive — CVS Caremark returns Zepbound to formulary
  3. Medicare.gov — Weight loss drugs (Medicare GLP-1 Bridge)

This guide covers coverage and access, not medical advice — whether a GLP-1 is right for you belongs with your prescriber. Formularies, PA criteria, and program terms change constantly; your plan documents and Lilly’s official pages are the authorities. We’re an independent publisher, not affiliated with or endorsed by Eli Lilly or any insurer — see our full medical disclaimer.